Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)
Technology appraisal
Summary (source: NICE)
Reference: TA1163
Type: Technology appraisal
Published: 4 June 2026
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation) is technology appraisal TA1163, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 4 June 2026. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.